Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
36.77
+0.25 (0.68%)
At close: Aug 14, 2026, 4:00 PM EDT
36.75
-0.02 (-0.05%)
After-hours: Aug 14, 2026, 7:50 PM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.14B in the quarter ending June 30, 2026, a decrease of -0.81%. This brings the company's revenue in the last twelve months to $17.32B, up 4.13% year-over-year. In the year 2025, Teva Pharmaceutical had annual revenue of $17.26B with 4.32% growth.
Revenue (ttm)
$17.32B
Revenue Growth
+4.13%
P/S Ratio
2.47
Revenue / Employee
$510,015
Employees
33,950
Market Cap
42.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.42B |
| Haleon | 14.80B |
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
TEVA News
- 1 day ago - Humana agrees not to reference Teva's Israel ties at US drug trial - Reuters
- 2 days ago - TEVA Maintained by Barclays -- Price Target Raised to $42.00 - GuruFocus
- 7 days ago - Teva (TEVA) Q2 2026 Earnings Call Transcript - The Motley Fool
- 7 days ago - SUPN vs. TEVA: Which Stock Should Value Investors Buy Now? - Nasdaq
- 8 days ago - Teva seeks to keep Israel ties from jury, cites Gaza war - Reuters
- 12 days ago - Why Teva Pharmaceutical Stock Surged This Week - The Motley Fool
- 15 days ago - Teva Pharmaceutical Industries Q2 Earnings Call Highlights - MarketBeat
- 16 days ago - TEVA SWOT Analysis: Financial Struggles Amidst Strategic Shifts Revealed in 10-Q Filing - GuruFocus